open access

Vol 90, No 1 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-01-31
Get Citation

Decreased Filamin b expression regulates trophoblastic cells invasion through ERK/MMP-9 pathway in pre-eclampsia

Jufeng Wei, Yufen Fu, Xiaoling Mao, Yuhui Jing, Jiangbo Guo, Yuanhua Ye
DOI: 10.5603/GP.2019.0006
·
Pubmed: 30756369
·
Ginekol Pol 2019;90(1):39-45.

open access

Vol 90, No 1 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-01-31

Abstract

Objectives: The purpose of this study was to investigate the expression of Filamin b in the placental placenta of patients with early or late onset pre-eclampsia (PE) and its potential effects on the pathophysiology of the disease.

Methods and methods: Immunohistochemistry staining, western blot assays and real time PCR were used to detect the expression level of FLN-b. The expression levels of MMP-2, MMP-9 and ERK1/2 proteins from control and FLN-b-silenced JEG-3 cells were also detected by western blot and JEG-3 cell invasion.

Results: Compared with normal term pregnancies placentas, the FLN-b expression was significantly lower than that of women with PE, its level in late-onset PE is lower than in early-onset PE. In FLN-b-silenced JEG-3 cells, the protein levels of MMP-2, MMP-9 and phosphorylated ERK1/2 decreased markedly and the number of cells penetrating through the transwell chamber membrane is also greatly reduced.

Conclusions: Down-regulation of FLN-b inhibits the ERK/MMP-2 and MMP-9 pathways, leading to trophoblastic invasion disorders in the PE placenta.  

Abstract

Objectives: The purpose of this study was to investigate the expression of Filamin b in the placental placenta of patients with early or late onset pre-eclampsia (PE) and its potential effects on the pathophysiology of the disease.

Methods and methods: Immunohistochemistry staining, western blot assays and real time PCR were used to detect the expression level of FLN-b. The expression levels of MMP-2, MMP-9 and ERK1/2 proteins from control and FLN-b-silenced JEG-3 cells were also detected by western blot and JEG-3 cell invasion.

Results: Compared with normal term pregnancies placentas, the FLN-b expression was significantly lower than that of women with PE, its level in late-onset PE is lower than in early-onset PE. In FLN-b-silenced JEG-3 cells, the protein levels of MMP-2, MMP-9 and phosphorylated ERK1/2 decreased markedly and the number of cells penetrating through the transwell chamber membrane is also greatly reduced.

Conclusions: Down-regulation of FLN-b inhibits the ERK/MMP-2 and MMP-9 pathways, leading to trophoblastic invasion disorders in the PE placenta.  

Get Citation

Keywords

Filamin b; preeclampsia; placenta; invasion; ERK1/2

About this article
Title

Decreased Filamin b expression regulates trophoblastic cells invasion through ERK/MMP-9 pathway in pre-eclampsia

Journal

Ginekologia Polska

Issue

Vol 90, No 1 (2019)

Pages

39-45

Published online

2019-01-31

DOI

10.5603/GP.2019.0006

Pubmed

30756369

Bibliographic record

Ginekol Pol 2019;90(1):39-45.

Keywords

Filamin b
preeclampsia
placenta
invasion
ERK1/2

Authors

Jufeng Wei
Yufen Fu
Xiaoling Mao
Yuhui Jing
Jiangbo Guo
Yuanhua Ye

References (25)
  1. Cornelius DC. Preeclampsia: From Inflammation to Immunoregulation. Clin Med Insights Blood Disord. 2018; 11: 1179545X17752325.
  2. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308(5728): 1592–1594.
  3. Maynard SE, Venkatesha S, Thadhani R, et al. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res. 2005; 57(5 Pt 2): 1R–7R.
  4. Stossel TP, Condeelis J, Cooley L, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol. 2001; 2(2): 138–145.
  5. Zhou X, Borén J, Akyürek LM. Filamins in cardiovascular development. Trends Cardiovasc Med. 2007; 17(7): 222–229.
  6. Zhou AX, Hartwig JH, Akyürek LM. Filamins in cell signaling, transcription and organ development. Trends Cell Biol. 2010; 20(2): 113–123.
  7. Guedj N, Zhan Q, Perigny M, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009; 51(1): 93–101.
  8. Li C, Yu S, Nakamura F, et al. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest. 2009; 119(9): 2725–2736.
  9. Bedolla RG, Wang Yu, Asuncion A, et al. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009; 15(3): 788–796.
  10. Alper O, Stetler-Stevenson WG, Harris LN, et al. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci. 2009; 100(9): 1748–1756.
  11. Bandaru S, Zhou AX, Rouhi P, et al. Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A. Oncogenesis. 2014; 3: e119.
  12. Iguchi Y, Ishihara S, Uchida Y, et al. Filamin B Enhances the Invasiveness of Cancer Cells into 3D Collagen Matrices. Cell Struct Funct. 2015; 40(2): 61–67.
  13. Thompson TG, Chan YM, Hack AA, et al. Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. J Cell Biol. 2000; 148(1): 115–126.
  14. Kalhori V, Törnquist K. MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells. Mol Cell Endocrinol. 2015; 404: 113–122.
  15. McCain J. The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T. 2013; 38(2): 96–108.
  16. Davidson B, Givant-Horwitz V, Lazarovici P, et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis. 2003; 20(7): 621–631.
  17. Ferretti C, Bruni L, Dangles-Marie V, et al. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2007; 13(2): 121–141.
  18. Cohen M, Bischof P. Factors regulating trophoblast invasion. Gynecol Obstet Invest. 2007; 64(3): 126–130.
  19. Husslein H, Haider S, Meinhardt G, et al. Expression, regulation and functional characterization of matrix metalloproteinase-3 of human trophoblast. Placenta. 2009; 30(3): 284–291.
  20. Xu B, Nakhla S, Makris A, et al. TNF-α inhibits trophoblast integration into endothelial cellular networks. Placenta. 2011; 32(3): 241–246.
  21. Saito S, Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. J Reprod Immunol. 2014; 101-102: 80–88.
  22. Zou J, Xu Li, Ju Y, et al. Cholesterol depletion induces ANTXR2-dependent activation of MMP-2 via ERK1/2 phosphorylation in neuroglioma U251 cell. Biochem Biophys Res Commun. 2014; 452(1): 186–190.
  23. Zhou X, Tian F, Sandzén J, et al. Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc Natl Acad Sci U S A. 2007; 104(10): 3919–3924.
  24. Bandaru S, Zhou AX, Rouhi P, et al. Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A. Oncogenesis. 2014; 3: e119.
  25. Jia RZ, Rui C, Li JY, et al. CDX1 restricts the invasion of HTR-8/SVneo trophoblast cells by inhibiting MMP-9 expression. Placenta. 2014; 35(7): 450–454.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl